These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 18472988)

  • 1. A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD).
    Kalaitzakis E; Björnsson E
    Ther Clin Risk Manag; 2007 Aug; 3(4):653-63. PubMed ID: 18472988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
    Zheng RN
    World J Gastroenterol; 2009 Feb; 15(8):990-5. PubMed ID: 19248200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lansoprazole plus levosulpiride versus esomeprazole in participants with gastroesophageal reflux disease and erosive esophagitis: a double blinded randomized control trial.
    Umer MR; Mejia Crespo WE; Dugan S; Javed H; Suleman M; Afzal MW; Mumtaz H; Saqib M; Malik HM; Iftikhar M
    Ann Med Surg (Lond); 2023 Oct; 85(10):4866-4876. PubMed ID: 37811050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
    Li MJ; Li Q; Sun M; Liu LQ
    Medicine (Baltimore); 2017 Sep; 96(39):e8120. PubMed ID: 28953640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity does not affect treatment outcomes with proton pump inhibitors.
    Sharma P; Vakil N; Monyak JT; Silberg DG
    J Clin Gastroenterol; 2013 Sep; 47(8):672-7. PubMed ID: 23442835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
    Richter JE; Kahrilas PJ; Johanson J; Maton P; Breiter JR; Hwang C; Marino V; Hamelin B; Levine JG;
    Am J Gastroenterol; 2001 Mar; 96(3):656-65. PubMed ID: 11280530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole.
    Guimarães EV; Guerra PV; Penna FJ
    Ther Clin Risk Manag; 2010 Oct; 6():531-7. PubMed ID: 21063463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
    Freston JW
    Am J Med; 2004 Sep; 117 Suppl 5A():14S-22S. PubMed ID: 15478848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic management of gastroesophageal reflux disease.
    Ramakrishnan A; Katz PO
    Curr Gastroenterol Rep; 2002 Jun; 4(3):218-24. PubMed ID: 12010622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esomeprazole: a review of its use in the management of acid-related disorders.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management.
    Orr WC
    Eur J Gastroenterol Hepatol; 2005 Jan; 17(1):113-20. PubMed ID: 15647651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of esomeprazole in patients with acid-peptic disorders.
    Beck J
    Gastroenterol Nurs; 2004; 27(2):44-9. PubMed ID: 15082946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of esomeprazole in the treatment of acid disorders.
    Johnson DA
    Expert Opin Pharmacother; 2003 Feb; 4(2):253-64. PubMed ID: 12562316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis.
    Raghunath AS; Green JR; Edwards SJ
    Clin Ther; 2003 Jul; 25(7):2088-101. PubMed ID: 12946553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.